Skip to main content
. 2015 Feb 18;10(2):e0117051. doi: 10.1371/journal.pone.0117051

Figure 2. Intracellular accumulation and glucuronidation of β-lap in colon cancer cells.

Figure 2

HT29 cells were pretreated with propofol (100 μM) for 1 h or UGT1A siRNA for 24 h. Cells were exposed to β-lap (5 μM) for indicated time. (A) Intracellular β-lap level in HCT116 is much higher than in HT29 cells; (B) Propofol or siRNA pretreatment lead to intracellular accumulation of β-lap in HT29 cells; (C) Propofol or siRNA pretreatment decreases intracellular M2 level in HT29 cells; (D) Propofol or siRNA pretreatment decreases M2 level in HT29 cell culture medium. Data are shown as mean 3 ± SEM of at least three independent experiments (*P<0.05, **P<0.01, ***P<0.001, propofol or UGT1A siRNA pretreatment vs. control cells).